Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Vor Biopharma Inc (VOR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: VOR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $46.75
1 Year Target Price $46.75
| 0 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.68% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 199.17M USD | Price to earnings Ratio - | 1Y Target Price 46.75 |
Price to earnings Ratio - | 1Y Target Price 46.75 | ||
Volume (30-day avg) 5 | Beta 2.08 | 52 Weeks Range 2.62 - 65.80 | Updated Date 10/17/2025 |
52 Weeks Range 2.62 - 65.80 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -273.6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -121.29% | Return on Equity (TTM) -125.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 50836308 | Price to Sales(TTM) - |
Enterprise Value 50836308 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.09 | Shares Outstanding 6853907 | Shares Floating 3211037 |
Shares Outstanding 6853907 | Shares Floating 3211037 | ||
Percent Insiders 30.48 | Percent Institutions 40.77 |
Upturn AI SWOT
Vor Biopharma Inc
Company Overview
History and Background
Vor Biopharma Inc. was founded in 2015. They are a clinical-stage cell therapy company focused on developing engineered hematopoietic stem cells (eHSCs) to create next-generation, treatment regimens for patients with cancer. The company's approach is to engineer HSCs to remove target antigens, such as CD33, creating cells that are resistant to specific therapies. This allows for higher doses of targeted therapies, aiming to improve patient outcomes.
Core Business Areas
- eHSC Platform: Development and clinical trials of engineered hematopoietic stem cell (eHSC) therapies for hematological malignancies.
Leadership and Structure
Dr. Robert Ang is the CEO. The company has a board of directors and a management team focused on clinical development, research, and corporate operations.
Top Products and Market Share
Key Offerings
- Trem-cel: Vor's lead candidate, trem-cel, is an eHSC product candidate engineered to remove CD33, a target antigen present on leukemia cells and normal myeloid cells. It is currently in clinical trials. Specific market share data or revenue figures are not publicly available, as the product is still in development. Competitors include companies developing alternative CD33-targeting therapies and other HSC transplantation strategies.
Market Dynamics
Industry Overview
The industry is focused on developing novel cell therapies and immunotherapies for cancer. There is significant interest in HSC transplantation and engineering to improve outcomes for patients with hematological malignancies.
Positioning
Vor Biopharma is positioning itself as a leader in the field of eHSC therapies, specifically targeting CD33-positive hematological malignancies. Their competitive advantage lies in their proprietary eHSC engineering platform.
Total Addressable Market (TAM)
The TAM for hematological malignancy therapies is substantial, estimated in the billions of dollars annually. Vor Biopharma is positioned to capture a portion of this market with their novel eHSC therapy. The exact TAM varies depending on specific disease types and treatment modalities.
Upturn SWOT Analysis
Strengths
- Proprietary eHSC engineering platform
- Strong intellectual property position
- Experienced management team
- Clinical-stage lead product candidate
Weaknesses
- Reliance on a single technology platform
- Clinical development risks
- High cash burn rate
- Limited commercial experience
Opportunities
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
- Advancements in cell engineering technologies
- Positive clinical trial results
Threats
- Competition from other cell therapy companies
- Regulatory hurdles
- Manufacturing challenges
- Reimbursement issues
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- NTLA
- BEAM
Competitive Landscape
Vor Biopharma faces competition from companies developing various cancer therapies, including cell therapies, immunotherapies, and targeted therapies. Their eHSC platform offers a unique approach, but it is unproven.
Growth Trajectory and Initiatives
Historical Growth: Vor Biopharma's historical growth is characterized by advancements in clinical development and pipeline expansion.
Future Projections: Future growth depends on the success of clinical trials and regulatory approvals. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing the trem-cel clinical program and exploring new applications of their eHSC platform.
Summary
Vor Biopharma is a clinical-stage company with a promising eHSC technology platform. Its success hinges on the clinical trial outcomes of trem-cel. The company faces challenges including clinical development risks and competition. Positive clinical data and partnerships could significantly enhance its prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Vor Biopharma Inc. SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vor Biopharma Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-02-05 | Chairman & CEO Dr. Jean-Paul Kress M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 154 | Website https://www.vorbio.com |
Full time employees 154 | Website https://www.vorbio.com | ||
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.